Context Therapeutics Announces Key Upcoming Investor Events

Author: Henry Turner Updated: 10-28-2025 08:01 AM

Context Therapeutics' Participation in Notable Investor Conferences

Context Therapeutics Inc. (NASDAQ: CNTX), a forward-thinking biopharmaceutical company focused on T cell engaging bispecific antibodies for solid tumors, is excited to share its upcoming involvement in several significant investor conferences. These gatherings present a wonderful opportunity for Context to connect with investors and industry experts while showcasing its innovative advancements in cancer treatments.

Details of the Upcoming Conferences

Context Therapeutics will take part in two prominent investor conferences where the company's leadership team will engage with participants. Below are the details of the conferences:

**Guggenheim 2nd Annual Healthcare Innovation Conference**
Dates: November 10-12
Fireside Chat: November 10 at 3:00 PM ET
1x1 Meetings: November 10
**Stifel 2025 Healthcare Conference**
Dates: November 11-13
Presentation: November 12 at 10:00 AM ET
1x1 Meetings: November 12

These events are pivotal for Context, as they allow for meaningful dialogue with potential investors and partners about the company's innovative product pipeline.

Webcast Information

A live webcast of the presentation from these conferences will be accessible through the News and Events section on Context Therapeutics' official website. Following the live sessions, replays will also be available for 90 days, ensuring that interested parties can catch up on the content at their convenience.

About Context Therapeutics Inc.

Context Therapeutics stands out in the biopharmaceutical field with its unique focus on T cell engaging bispecific therapeutics, essential for the treatment of various solid tumors. Notable products in their portfolio include CTIM-76 (a Claudin 6 x CD3 TCE), CT-95 (a Mesothelin x CD3 TCE), and CT-202 (a Nectin-4 x CD3 TCE). The company's ongoing commitment to research and development positions it as a key player in oncology treatment advancements.

Contact and Additional Information

For those interested in learning more or arranging a meeting with Context's management during these conferences, please do not hesitate to reach out. Contact Jennifer Minai-Azary, Chief Financial Officer, for further inquiries via email at IR@contexttherapeutics.com.

Frequently Asked Questions

1. What is the focus of Context Therapeutics?

Context Therapeutics specializes in developing T cell engaging bispecific antibodies aimed at treating solid tumors effectively.

2. When will Context present at the upcoming conferences?

Context will present at the Guggenheim Conference on November 10 and at the Stifel Conference on November 12.

3. How can I access the company’s presentations?

The presentations will be available via a live webcast on Context Therapeutics' official website, with replays accessible afterward.

4. Who can provide more information about Context Therapeutics?

For more information, you can contact Jennifer Minai-Azary, CFO of Context Therapeutics, at their investor relations email.

5. What innovative products does Context Therapeutics develop?

Context is developing a variety of bispecific therapeutic products including CTIM-76, CT-95, and CT-202 targeting various solid tumors.

About The Author

Hi there, As a writer and financial specialist, Henry Turner is passionate about guiding people through the complex world of finance. Having worked in finance for many years, I am an expert at simplifying difficult financial ideas into understandable, useful insights for my blog and articles. My goal is to arm you with the confidence and information you need to make wise financial choices.

Writing for a number of financial blogs has allowed me to interact with readers from novice investors looking for fresh ideas to seasoned investors starting their financial journeys. My mission is to enable everyone to understand and access finance, so enabling you to confidently and clearly reach your financial goals. I appreciate you traveling with me toward success and financial literacy.

Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.